Loading…
← CockpitCompetitor Analysis › 688331.SS RemeGen Co. Ltd. Class AOpen in the cockpit ↗

RemeGen Co. Ltd. Class A688331.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese biotech developing antibody-drug conjugates and biologics for autoimmune disease and cancer.

≈ A Chinese Seagen/Horizon Therapeutics hybridMomentum weak 23
Mkt cap
$6.28B
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$91.8M
20-day average traded
Fwd P/E
10.8×
forward earnings
ROIC−WACC
+95.7 pp
WACC 12.3%
Hurdle
-302 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥86.70
1D-1.8%
1W-12.6%
1M-13.3%
3M-34.2%
6M-24.4%
YTD+11.4%
1Y-10.4%
ATR %6.5%
52w lowhigh45.1% off high

What RemeGen does

Chinese biotech developing antibody-drug conjugates and biologics for autoimmune disease and cancer.

Earns from sales of its two lead drugs in China, mostly to hospitals, and from licensing: overseas rights to disitamab vedotin were licensed to Seagen, now part of Pfizer, bringing upfront and milestone payments. This is its Shanghai STAR market listing; the same company also lists in Hong Kong.

In one line: A Chinese Seagen/Horizon Therapeutics hybrid.

Products and services

  • Telitacicept (autoimmune biologic)
  • Disitamab vedotin (HER2 ADC)
  • Pipeline biologics

Customers

  • Hospitals
  • Licensing partners (ex-China)

Where it sits in the supply chain

  • Biotechnology
  • Antibody & ADC drug development
  • Autoimmune and oncology therapeutics

What could go right

  • Ex-China licensing deals
  • Label expansion for lead drugs

What could go wrong

  • Clinical trial risk
  • Reliance on a few lead assets

Moat: narrow (IP / patents, scale). Proprietary ADC and dual-target biologic platform with first-in-class assets in China.

Headquarters: Yantai, China · Founded: 2008 · Employees: 3,048

Named competitors

RemeGen at a glance

Size RemeGen (688331.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.28B, the 372nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥86.70 on 18 Nov 2026.

Performance Over six months the shares fell 24.4%, against -4.5% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 272.3% over the last twelve months (peer median +12.5%); the operating margin is 60.9% (peer median 15.8%).

Valuation It trades at 10.8× forward earnings against a peer median of 25.1× (2nd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +303%, so the hurdle is -302 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 95.7 points above its cost of capital (12.3% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 96688331.SS 77
Six months, rebased to 100: RemeGen against the median of its 20 peers (local-currency closes).

RemeGen financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥8.29BCN¥3.25BCN¥1.71BCN¥1.08BCN¥772M
Revenue growth—+90%+58%+40%—
Gross profitCN¥7.83BCN¥2.62BCN¥1.18BCN¥661MCN¥363M
EBITDAn/aCN¥451M-CN¥1.16B-CN¥1.34B-CN¥1.02B
Net incomeCN¥6.53BCN¥710M-CN¥1.47B-CN¥1.51B-CN¥999M
Free cash flowCN¥3.80B-CN¥144M-CN¥1.51B-CN¥2.35B-CN¥2.00B
Capital expenditureCN¥133MCN¥200MCN¥265MCN¥853MCN¥753M
Total debtCN¥292MCN¥2.20BCN¥2.67BCN¥1.27BCN¥278M

Quarterly statements and history in the cockpit →

RemeGen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%BIOCONBLTE0126Z0ORKAMIRMSUPN000999LGNDALKEM000963ABBOTINDIAGLAND9926BANB6030876821IBRXCYTK688331.SS6-month return →1-month return →
Up and to the right = strong over both horizons. RemeGen is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×60×BIOCONAPTXSUPN000999LGNDALKEMABBOTINDIAGLAND4528688331.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. RemeGen is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%APTXSUPN000999LGNDALKEM688331.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. RemeGen is the large dot.

RemeGen competitors and peer comparison

Head to head with its named competitors (688331.SS vs 1877.HK vs 1801.HK vs 6990.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
RemeGen 688331.SS$6.28B-24%+272%61%10.8×1.1%
Shanghai Junshi Biosciences 1877.HK$3.49B-38%+36%-14%n/an/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HK$13.0B-1%+44%-38%1,176.1×55.3%

How RemeGen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

RemeGen against its 20 peers (data as of 18 Nov 2026)
Measure688331.SSPeer medianRank in peer set
1-month return-13.3%-0.3%6th lowest of 21
6-month return-24.4%-4.5%5th lowest of 20
Distance from 52-week high-45.1%-20.4%5th lowest of 21
Revenue growth (TTM)+272.3%+12.5%highest of 18
Operating margin60.9%15.8%highest of 19
Forward P/E10.8×25.1×2nd cheapest of 15
Growth the price implies (Req g, 7 yrs)1.1%6.2%5th least demanding of 10
Growth delivered (Del g)+303.3%+10.7%highest of 10
Hurdle (Req g minus delivered)-302.3 pp-7.7 ppleast demanding of 10
ROIC minus cost of capital+95.7 pp+1.9 pphighest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
RemeGen 688331.SSChina$6.28B-24%+272%61%10.8×1.1%+303.3%
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%

Questions

Who are RemeGen's main competitors?
Named competitors: Junshi Biosciences (1877.HK), Innovent Biologics (1801.HK), Kelun-Biotech (6990.HK), Seagen (private or unlisted). The cockpit's measured peer set (industry) also includes Biocon (BIOCON.NS), Belite Bio, Inc. ADR (BLTE), Samsung Epis (0126Z0.KS), Oruka Therapeutics (ORKA), Mirum Pharmaceuticals (MIRM), Apotex Health (APTX.TO).
Is RemeGen expensive compared with its peers?
On forward p/e it trades at 10.8× against a peer median of 25.1×, 2nd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +303%, so the hurdle is -302 pp: the price already allows for a slowdown.
How has RemeGen stock performed?
Over six months to 18 Nov 2026 the shares returned -24.4% against -4.5% for the median peer; over one year -10.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.